Rebound of clinical disease activity after fingolimod discontinuation? A nationwide cohort study of patients in Denmark
Elisabeth Framke(Copenhagen University Hospital), Melinda Magyari(University of Copenhagen), Finn Sellebjerg(Kaiser Permanente), Luigi Pontieri(Rigshospitalet), Stephan Bramow(Copenhagen University Hospital)
Cited by 9
Related Papers
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
|Science|2019|1.4k
Worldwide Incidence and Prevalence of Neuromyelitis Optica
|Neurology|2020|303
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
|CNS Drugs|2014|293
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis
|JAMA Neurology|2021|237
Apparent changes in the epidemiology and severity of multiple sclerosis
|Nature Reviews Neurology|2021|209